Caleb M. Radens

Caleb M. Radens

Auto-generated profile, based on publicly available information

Caleb M. Radens

Cell and Molecular Biology Graduate Group, University of Pennsylvania, Philadelphia, Pennsylvania. 5

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2014 in Biosensors and Bioelectronics
Verified
Journal Article
Closed access
DWDylan P. Webster
Dylan P. Webster
MTMichaela A. TerAvest
Michaela A. TerAvest
DDDevin F.R. Doud
Devin F.R. Doud
ACArun Chakravorty
Arun Chakravorty
EHEric C. Holmes
Eric C. Holmes
LALargus Angenent
Largus Angenent

1 May 2016 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
GGGabriela Gonzalez-Perez
Gabriela Gonzalez-Perez
AHAllison L. Hicks
Allison L. Hicks
TTTessa M. Tekieli
Tessa M. Tekieli
CRCaleb M. Radens
Caleb M. Radens
BWBrent L. Williams
Brent L. Williams
ELEsi S. N. Lamousé-Smith
Esi S. N. Lamousé-Smith
Microbial colonization of the infant gastrointestinal tract (GIT) begins at birth, is shaped by the maternal microbiota, and is profoundly altered by antibiotic treatment. Antibiotic treatment of mothers during pregnancy influences colonization of the GIT microbiota of their infants. The role of the GIT microbiota in regulating adaptive immune function against systemic viral infections during infancy remains undefined. We used a mouse model of perinatal antibiotic exposure to examine the effect of GIT microbial dysbiosis on infant CD8+ T cell–mediated antiviral immunity. Maternal antibiotic treatment/treated (MAT) during pregnancy and lactation resulted in profound alterations in the composition of the GIT microbiota in mothers and infants. Streptococcus spp. dominated the GIT microbiota of MAT mothers, whereas Enterococcus faecalis predominated within the MAT infant GIT. MAT infant mice subsequently exhibited increased and accelerated mortality following vaccinia virus infection. Ag-specific IFN-γ–producing CD8+ T cells were reduced in sublethally infected MAT infant mice. MAT CD8+ T cells from uninfected infant mice also demonstrated a reduced capacity to sustain IFN-γ production following in vitro activation. We additionally determined that control infant mice became more susceptible to infection if they were born in an animal facility using stricter standards of hygiene. These data indicate that undisturbed colonization and progression of the GIT microbiota during infancy are necessary to promote robust adaptive antiviral immune responses.

1 November 2017 in Developmental Cell
Verified
Journal Article
Closed access
ARAlex M. Rohacek
Alex M. Rohacek
TBThomas W. Bebee
Thomas W. Bebee
RTRichard K. Tilton
Richard K. Tilton
CRCaleb M. Radens
Caleb M. Radens
CMChris McDermott-Roe
Chris McDermott-Roe
DEDouglas J. Epstein
Douglas J. Epstein

1 November 2017 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
MSMansi Y. Shinde
Mansi Y. Shinde
Simone SidoliSimone Sidoli
Simone Sidoli
KKKatarzyna Kulej
Katarzyna Kulej
MMMichael J. Mallory
Michael J. Mallory
CRCaleb M. Radens
Caleb M. Radens
PKPeter S. Klein
Peter S. Klein
Glycogen synthase kinase-3 (GSK-3) is a constitutively active, ubiquitously expressed protein kinase that regulates multiple signaling pathways. In vitro kinase assays and genetic and pharmacological manipulations of GSK-3 have identified more than 100 putative GSK-3 substrates in diverse cell types. Many more have been predicted on the basis of a recurrent GSK-3 consensus motif ((pS/pT)XXX(S/T)), but this prediction has not been tested by analyzing the GSK-3 phosphoproteome. Using stable isotope labeling of amino acids in culture (SILAC) and MS techniques to analyze the repertoire of GSK-3–dependent phosphorylation in mouse embryonic stem cells (ESCs), we found that ∼2.4% of (pS/pT)XXX(S/T) sites are phosphorylated in a GSK-3–dependent manner. A comparison of WT and Gsk3a;Gsk3b knock-out (Gsk3 DKO) ESCs revealed prominent GSK-3–dependent phosphorylation of multiple splicing factors and regulators of RNA biosynthesis as well as proteins that regulate transcription, translation, and cell division. Gsk3 DKO reduced phosphorylation of the splicing factors RBM8A, SRSF9, and PSF as well as the nucleolar proteins NPM1 and PHF6, and recombinant GSK-3β phosphorylated these proteins in vitro. RNA-Seq of WT and Gsk3 DKO ESCs identified ∼190 genes that are alternatively spliced in a GSK-3–dependent manner, supporting a broad role for GSK-3 in regulating alternative splicing. The MS data also identified posttranscriptional regulation of protein abundance by GSK-3, with ∼47 proteins (1.4%) whose levels increased and ∼78 (2.4%) whose levels decreased in the absence of GSK-3. This study provides the first unbiased analysis of the GSK-3 phosphoproteome and strong evidence that GSK-3 broadly regulates alternative splicing.

29 September 2017 in PLOS Biology
Verified
Journal Article
Open access
PDF file
LBLauren K Brady
Lauren K Brady
HWHejia Wang
Hejia Wang
CRCaleb M Radens
Caleb M Radens
YBYue Bi
Yue Bi
MRMilan Radovich
Milan Radovich
CKConstantinos Koumenis
Constantinos Koumenis
Cells adjust to hypoxic stress within the tumor microenvironment by downregulating energy-consuming processes including translation. To delineate mechanisms of cellular adaptation to hypoxia, we performed RNA-Seq of normoxic and hypoxic head and neck cancer cells. These data revealed a significant down regulation of genes known to regulate RNA processing and splicing. Exon-level analyses classified > 1,000 mRNAs as alternatively spliced under hypoxia and uncovered a unique retained intron (RI) in the master regulator of translation initiation, EIF2B5. Notably, this intron was expressed in solid tumors in a stage-dependent manner. We investigated the biological consequence of this RI and demonstrate that its inclusion creates a premature termination codon (PTC), that leads to a 65kDa truncated protein isoform that opposes full-length eIF2Bε to inhibit global translation. Furthermore, expression of 65kDa eIF2Bε led to increased survival of head and neck cancer cells under hypoxia, providing evidence that this isoform enables cells to adapt to conditions of low oxygen. Additional work to uncover -cis and -trans regulators of EIF2B5 splicing identified several factors that influence intron retention in EIF2B5: a weak splicing potential at the RI, hypoxia-induced expression and binding of the splicing factor SRSF3, and increased binding of total and phospho-Ser2 RNA polymerase II specifically at the intron retained under hypoxia. Altogether, these data reveal differential splicing as a previously uncharacterized mode of translational control under hypoxia and are supported by a model in which hypoxia-induced changes to cotranscriptional processing lead to selective retention of a PTC-containing intron in EIF2B5. Tumor hypoxia is a negative prognostic factor for many solid cancers. Cellular adaptation to hypoxia is largely mediated by widespread changes in gene expression and enables cancer cells to adjust and survive. Recently, alternative splicing has been implicated in this process. To identify biologically impactful hypoxia-responsive isoforms, we took an unbiased approach to deeply sequence RNA of normoxic and hypoxic head and neck cancer cells. This analysis identified >1,000 mRNAs as alternatively spliced under hypoxia, including a significant enrichment of alternatively spliced genes involved in adaptation to hypoxia. Most notably, we discovered a unique retained intron in the translation initiation factor EIF2B5 that creates a premature termination codon. We show that this retained intron leads to a 65kDa truncated isoform that opposes full-length eIF2Bε to inhibit global translation and enhances survival of head and neck cancer cells under hypoxia. Strikingly, this intron and several additional hypoxia-induced retained introns were overexpressed in solid tumors relative to normal tissues. Mechanistically, we propose that intron retention under hypoxia is influenced by changes to RNA polymerase II (RNAPII) activity at weak 3′ splice sites and carry out experimental validation for the retained intron in EIF2B5 to investigate intron retention under hypoxia.

2 August 2024 in Cancer Research
Verified
Journal Article
Open access
PDF file
MTManuel Torres-Diz
Manuel Torres-Diz
CRClara Reglero
Clara Reglero
CFCatherine D. Falkenstein
Catherine D. Falkenstein
ACAnnette Castro
Annette Castro
KHKatharina E. Hayer
Katharina E. Hayer
ATAndrei Thomas-Tikhonenko
Andrei Thomas-Tikhonenko
Relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) is a major cause of pediatric cancer–related deaths. Relapse-specific mutations do not account for all chemotherapy failures in B-ALL patients, suggesting additional mechanisms of resistance. By mining RNA sequencing datasets of paired diagnostic/relapse pediatric B-ALL samples, we discovered pervasive alternative splicing (AS) patterns linked to relapse and affecting drivers of resistance to glucocorticoids, antifolates, and thiopurines. Most splicing variations represented cassette exon skipping, “poison” exon inclusion, and intron retention, phenocopying well-documented loss-of-function mutations. In contrast, relapse-associated AS of NT5C2 mRNA yielded an isoform with the functionally uncharacterized in-frame exon 6a. Incorporation of the 8-amino acid sequence SQVAVQKR into this enzyme created a putative phosphorylation site and resulted in elevated nucleosidase activity, which is a known consequence of gain-of-function mutations in NT5C2 and a common determinant of 6-mercaptopurine resistance. Consistent with this finding, NT5C2ex6a and the R238W hotspot variant conferred comparable levels of resistance to 6-mercaptopurine in B-ALL cells both in vitro and in vivo. Furthermore, both NT5C2ex6a and the R238W variant induced collateral sensitivity to the inosine monophosphate dehydrogenase inhibitor mizoribine. These results ascribe to splicing perturbations an important role in chemotherapy resistance in relapsed B-ALL and suggest that inosine monophosphate dehydrogenase inhibitors, including the commonly used immunosuppressive agent mycophenolate mofetil, could be a valuable therapeutic option for treating thiopurine-resistant leukemias. Significance: Alternative splicing is a potent mechanism of acquired drug resistance in relapsed/refractory acute lymphoblastic leukemias that has diagnostic and therapeutic implications for patients who lack mutations in known chemoresistance genes.